ALPN News and Press, Alpine Immune Sciences Inc. From 05/15/19

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatmen...

Alpine Immune Sciences (NASDAQ: ALPN ): Q1 GAAP EPS of -$0.70 misses by $0.01 . More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Alpine transitions to clinical-stage company Completed financing to fund further development of both lead programs Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/in...

Alpine Immune Sciences, Inc. (Nasdaq: ALPN) (“Alpine”), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced Stanford Peng, M.D. Ph.D., has been appointed President an...

Alpine Immune Sciences (NASDAQ: ALPN ): FY GAAP EPS of -$2.63 misses by $0.01 . Revenue of $0.71M (-59.0% Y/Y) misses by $0.18M . Press Release More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, ,

First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 Completed $25 Million Private Placement Strong Financial Position to Transition Two Lead Programs ALPN-101 and ALPN-202 into Patients Alpine Immune Sciences, Inc. ...

The following slide deck was published by Alpine Immune Sciences, Inc. in conjunction with this Read more ...

Those who exploit the suffering of others are called parasites. Those who exploit their own suffering are called artists. ” ― Marty Rubin Today, we take a look at a promising but very early stage 'Tier 4' developmental concern that recently came onto my radar. Company Ove...

By Steve Brown Dr. Hung Tran of BioSci Capital Partners shares his wisdom and experience as it applies to investing in the biotech arena on his marketplace service Integrated BioSci Investing . Dr. Tran's goal is to help make this complicated sector accessible to the average invest...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor conferences in March. Cow...